Care after pancreatic resection according to an algorithm for early detection and minimally invasive management of pancreatic fistula versus current practice (PORSCH-trial): design and rationale of a nationwide stepped-wedge cluster-randomized trial
Hjalmar C. van Santvoort(University Medical Center Utrecht), Casper H.J. van Eijck(Erasmus MC), Marc G. Besselink(Amsterdam Neuroscience), Koop Bosscha(Jeroen Bosch Ziekenhuis), Mike S.L. Liem(Medisch Spectrum Twente), Bas Groot Koerkamp, Jennifer MJ Schreinemakers(Amphia Ziekenhuis), Mark Arntz(Radboud University Nijmegen), Olivier R. Busch(Amsterdam Neuroscience), Adriaan Moelker(Erasmus MC Cancer Institute), Ronald M. van Dam(Maastricht University Medical Centre), Gijs A. Patijn(Isala), Vincent E. de Meijer(University Medical Center Groningen), Otto M. van Delden(Amsterdam UMC Location University of Amsterdam), Bert A. Bonsing(Leiden University Medical Center), Krijn P. van Lienden(University of Amsterdam), Geert Kazemier(European Organisation for Research and Treatment of Cancer), Thomas L. Bollen, Inne H.M. Borel Rinkes(Utrecht University), Erwin van der Harst(Radboud University Nijmegen), Ignace H. J. T. de Hingh(Radboud University Nijmegen), Christiaan van der Leij(Maastricht University), Daniel van den Heuvel(Maastricht University), F. Jasmijn Smits(University Medical Center Utrecht), C. Henri van Werkhoven(University Medical Center Utrecht), Sebastiaan Festen(OLVG), B.M. van der Kolk(Radboud University Nijmegen), I. Quintus Molenaar(University Medical Center Utrecht), Anne Claire Henry(Erasmus MC), Daphne Roos(Amsterdam UMC Location University of Amsterdam), Fennie Wit(Slingeland Ziekenhuis)
Cited by 45
Related Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
|New England Journal of Medicine|2018|1.4k